InvestorsHub Logo
Followers 23
Posts 3078
Boards Moderated 0
Alias Born 07/15/2016

Re: thehumanchessmachine post# 36987

Tuesday, 09/19/2017 8:39:10 PM

Tuesday, September 19, 2017 8:39:10 PM

Post# of 65771
Evio lacks that kind of capital. What I suspect will happen down the road is evio will take another convertible note or 2 out and pay pallitech. Those shares will get cashed in by a note holder. Phytotech will default and cough up 1.3M worth of assets to evio which is probably the entire company. Evio will then own phyto outright.

See pallitech is a private company and wants cash not preferred shares or common stock from evio.

I see this as potentially a very well crafted shares based merger where note holders act as a middleman.

Now this could happen more often but I think once WW gets the pps and financials in a better position we could see real equity financing, but this is pretty damn crafty IMHO if I'm correct.

We will see more dilution for sure but no one complained last yr when dilution financed 5 labs and what is now the backbone of Evio today.

Will said on an OTC market podcast otcQX is next and NASDAQ in 18 months or so. They need more by way of assets to get there.

Until QX I don't see a chance in hell of attractive equity financing... Maybe not even until NASDAQ given this is a shifty area of business in the MJ industry